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ABSTRACT 
}lomogenates of testes from human fetuses of 12-16 weeks gestation 
were incubated in vitro with pregnenolone-4-14C and pregnenolone-7-3H- 
sulfate. Dehydroepiandrosterone sulfate and pregnenediol sulfate, each 
bearin~ the tritium label only, were identified in the conjugated fract- 
ion. Progesterone, 17~-hydroxyprogesterone, 17a-hydroxypregnenolone, 
dehydroepiandrosterone, androstenedione and testosterone, each bearinm 
both a tritium and 14C-label, were identified in the organic fraction. 
In a similar incubation, with pregnenolone-7-3H-sulfate-35S as sub- 
strate, the direct conversion to 17a-hydroxypregnenolone sulfate was 
demonstrated. The presence of slight sulfatase activity was also noted. 
The direct metabolism of steroid sulfates and the presence of sulfatase 
activity in this fetal tissue and the possible significance of these 
findings in the developing male fetus are discussed. 
INTRODUCTION 
Steroid sulfates are present in relatively large quantities in 
the human fetal circulation (i). Steroid sulfokinase activity has 
been demonstrated both in vivo and in vitro in the human fetal adrenal 
(2-5). Normal adult human testes possess this capacity as well (6,7). 
Neutral steroid sulfate secretion by normal human adult testes has 
been demonstrated recently (8). Although the metabolism of certain 
unconjugated steroids by human fetal testes has been studied (9-11), 
the metabolism of steroid sulfates by this tissue has not. 
Since steroid sulfates can be transformed to other steroid sulfates 
as well as to biolo~ically active hormones in both the fetus and the 
adult (12-23), it was felt of interest to study in_vitro the metabolic 
128 S.T E R O I D S 16:1 
fate of pregnenolone5 and pregnenolofie sulfate (PS) in human fetal 
testes. 
MATERIALS AND METHODS 
Human fetal testes were obtained from 3 fetuses of 12-16 weeks 
gestation at the time of hysterotomy for therapeutic termination of 
pregnancy. A segment of testis was removed from each fetus for his- 
tologic examination. Testicular tissue, weighing 17.6 mg from one 
fetus (crown-rump and crown-heel lengths of 75 mm and 102 mm respect- 
ively), used in incubation I was homogenized and immediately incubated, 
while testicular tissue weighing 43 mg from the two remaining fetuses 
(crown-rump and crown-heel lengths of one 86 mm and 125 mm respectively, 
and of the other 93 mm and 138 mm respectively), used in incubation 
2, was frozen at -70°C in liquid nitrogen and thawed immediately prior 
to homogenization and incubation. Tissues were homogenized in an all 
glass Potter-ElvehJem apparatus. 
Materials: Radioactive steroids were obtained from New England Nuclear 
Co. Pregnenolone-4-14C, specific activity (SA) 56 mCi/mmole (lot 236- 
75A-14) was purified by thin layer chromatography (TLC) in systems i 
and 2 (Table I). Pregnenolone-7-3H-sulfate, SA 20 Ci/mmole (lot 321- 
190) was purified by Cellte column partition chromatography (CPC) 
in system 3 and paper chromatography (PC) in system 4. Pregnenolone- 
7-3H-sulfate-35S was prepared by combining pregnenolone-7-3H-sulfate 
and pregnenolone sulfate-35S, (SA 12 mCi/mmole, lot 523004). The 
double labeled PS was purified in systems 3 and 4 and partitioned 
prior to use between organic solvent and water to remove unconjugated 
steroid. 
All organic solvents were analytical grade and redistilled prior 
to use. Crystalline steroids used as standards and carriers were 
obtained commercially and assessed for purity by recrystallization, 
chromatographic behavior and melting point determination before use. 
Co-factors were purchased from Sigma Chemical Co. 
The interconversion between ammnnium and pyridinium salts of 
steroid sulfates was accomplished by the method of McKenna and Norymberski 
(24). 
Incubation i: The homogenized tissue was incubated in a medium con- 
taining 1.74 ml of 0.15 M phosphate buffer pH 7.4, 1.8 ~Ci pregnenolone 
-4-14C, i0 ~Ci pregnenolone-7- N-sulfate, 1.49 ~moles ATP, 1.13 ~moles 
DPN, 1.01 ~moles TPN, 3.96 ~moles DL-isocltric acid and 200 ~g iso- 
citric dehydrogenase. Two drops of propylene glycol were added to 
dissolve the preguenolone-4-14C. The incubation was carried out in 
a Dubnoff metabolic incubator at 37oc for 3 hours using 95% 02 and 
5% C02 as the gas phase. The reaction was stopped by the addition 
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of dichloromethane, and the material was then partitioned between 
dichloromethane and water. 
Incubation 2: The homogenized tissue was added to a flask containinR 
pregnenolone-7-38-sulfate-35S (2936 x 104cpm 3H and 2343 x 103 cpm 355). 
The incubation medium contained Krebs-Ringer bicarbonate buffer, 2.98 
~moles ATP, 2.26 Nmoles DPN~ 2.02 ~moles TPN, 7.92 ~moles DL-isocitric 
acid and 400 ~IF isocitric dehydrogenase. The ratio of tissue (mg) 
to buffer (ml) was 20/1. Three tissueless control flasks and 2 in- 
activated tissue control flasks were prepared in a similar manner, 
but with 0.002 x the amount of PS. All flasks were incubated simul- 
taneously in a Dubnoff metabolic incubator at 37°C for 3 hours using 
air as the gas phase. The reaction was stopped by the addition of 
i0 ml of dichloromethane to each flask. Following extraction, the 
material from each flask was submitted to purification by CPC in system 
3 without prior partition into conjugated and unconjugated fractions. 
Table i. CHROMATOGRAPHIC SYSTEMS EF~LOYED 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
No. Solvents Ratios 
Type of 
Chromatography 
i Cyclohexane, ethyl acetate, ethanol 9:9:2 TLC * 
2 Benzene, ethanol 9:1 TLC 
3 Isooctane, t-butanol, IM NH40H 
4 Isopropyl ether, t-butanol, 
NH4OH, H20 
5 lleDtane, methanol, H20 
6 Toluene, isooctane, methanol, H20 










8 Cyclohexane, ethanol, 1120 
9 Heptane, benzene, methanol, H20 
i0 Isooctane, chloroform, n-butanol, 








* TLC = Thin layer chromatography 
** CPC = Column Dartition chromatography 
*** PC = Paper chromatography 
**** CCD = Countercurrent distribution 
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Isolation and identification of metabolites were performed using 
reverse isotope dilution techniques which included identical chroma- 
tographic behavior of the radioactive material and the steroid carrier 
under study in various chromatographic systems and successive recrysta]- 
lization until crystals and mother liquor agreed within 5% and were 
witllin 5v of mean value. 
Chromat0g_raphv: CPC usin~ Johns-Manville Celite No. 545, prev- 
iously washed as described by Kelly et al (25), as the support and 
PC using ~hatman No. i paper were performed as previously described 
(22). Thin layer chromatography (TLC) was carried out on silica gel 
G (Merck & Co., Darmstadt) as described by Lisboa and Diczfalusy (26). 
The systems used are listed in Table i and will be referred to in 
the text by number. 
Estimation of Steroids: The identification of non-radioactive 
sam~ies--has been des-c¥i-bed previously (23). Polar material was dis- 
solved in I ml methanol and 0.i ml of solubilizer (Nuclear Chicago 
Corp.) prior to the addition of the scintillation medium. Quench 
corrections were performed using an internal standard technique. 3H- 
and 14C-activity were expressed as dpm. 35S-activity is expressed 
as cDm after correcting for decay. Thin layer and paper chromatoRrams 
were scanned on a Packard radiochromatogram scanner Model 7200. 
Derivative formation was performed when sufficient material was 
available. Solvolysis was carried out using the method of Segal et 
al (27). Acetylation using acetic anhydride and anhydrous pyridine 
(1:2) was carried out at room temperature overnight. Saponification 
was accomplished by the method of Neher et al (28). 
RESULTS 
Incubation i 
Aaueous Fraction. Following dichloromethane/water partition 
.It . . . . . . . . . . . . .  
94.4% of the recovered 3H-labeled material and 1.2% of the recovered 
14C-labeled material were found in the aqueous fraction. However, 
after PC in system 4, 5 zones of radioactivity were observed, all 
of which contained only the tritium label. All of the 14C-labeled 
material migrated to the solvent front and was found to be pre~nenolone. 
Zone i (Rf=0.80): The radioactive material in this zone behaved 
in a similar fashion to carrier PS. This material was solvolyzed 
and submitted to PC in system 5. Two peaks were identified (Rf=0.45 
and 0.02). The less polar area, which behaved llke prep, nenolone, 
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was rerun in system 5 after authentic pregnenolone carrier was added. 
Both radioactive and crystalline material exhibited identical mobil- 
ity. It was concluded that this radioactive material represented un- 
converted substrate. 
The more polar area was submitted to PC in system 6. The major 
peak of radioactivity (Rf=0.90) was acetylated and run in system 7. 
An area similar to 5-pregnene-3~20~-diol diacetate (pregnenediol 
diacetate) (Rf=0.85) was identified. A portion of this material was 
submitted to countercurrent distribution (CCD) in system 8, A single 
peak (K=6.69) was observed associated with authentic carrier preg- 
nenediol diacetate. After additional carrier was added, the radio- 
active material was recrystallized to constant SA (Table 2). 
Zone 2 (Rf=0.64): This area was similar to 17~-hydroxypregnen- 
olone sulfate (17~-OH-PS). However, following solvolysis and chrom- 
atography in several systems, the identity of this metabolite could 
not be established definitely. 
Zone 3 (Rf=0.46): A portion of the radioactive material from this 
zone, which behaved like dehydroepiandrosterone sulfate (DHAS), was 
solvolyzed. After the addition of authentic dehydroepiandrosterone 
(DHA) carrier, this material was submitted to PC in system 7 for 50 
hours, and both radioactive and added crystalline material had identical 
mobilities (Rt=0.32). The material was then submitted to PC in system 
9 and the mobilities of carrier and radioactive material were again 
identical (Rf=0.57). The material was mixed with additional authentic 
DHA and recrystallized to constant SA as the unconjugated compound 
(Table 2). 
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Table 2. Radiochemical purity of steroid sulfates derived from 
incubation of fetal testicular homogenate with pregnenolone-7-3H 
sulfate and pregnenolone-4-14C. 
5-pregnene-3~,20~-diol dlacetate 




Rec rys ta l -  Rec rys ta l -  
Solvent lization dpm 3H*/mg Solvent lization dpm 3H*/mg 
methanol C I 411 methanol, C 1 87 
petroleum ether 
methanol C 2 397 methanol, C 2 71 
petroleum ether 
methanol C 3 404 methanol C 3 84 
ML 3 411 ML 3 91 
*14C-label was not found in these two metabolites 
C = Crystal ML = Mother Liquor 
Zone 4 and 5 (Rf=0.19 and 0.03 respectively). Despite further 
chromatography, the identity of this highly polar material could not 
be established before or after solvolysis. 
Organic Fraction. Initial chromatography was performed in system 
9. Several zones were identified. After further chromatography in 
appropriate systems and the addition of suitable cold carriers, the 
identity of the following unconJugated steroids was established by 
recrystalllzation to constant SA: pregnenolone, 17=-hydroxypregnen- 
olone, progesterone, 17~-hydroxyprogesterone, DHA, androstenedione 
and testosterone. Although losses were not calculated, DHA, 17=- 
hydroxypregnenolone and androstenedione appeared quantitatively to be 
the most important metabolites isolated (Table 3). 
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Table 3. Radlochemlcal purity of unconJugated steroids identified 
from incubation of fetal testicular homogenate with pregnenolone-7- 
3H sulfate and pregnenolone-4-14C (3H/14C = 5.56). 
S tero id Solvent 
Successive 
Recrystal- 





17~-hydroxy- Methanol, acetone 
























Testos terone*  N-hexane, acetone 
N-hexane, acetone 
* following acetylation 
C 1 2450 15336 
C 2 2492 155O9 
C 2454 15622 0.16 
ML~ 2429 15703 0.15 
C 1 253 3322 
C 2 197 3522 
C 102 3524 0.03 
ML~ 105 3507 0.03 
C 1 96 913 
C 2 93 901 
C 96 912 0.11 
ML~ 89 915 0.i0 
C 1 1069 7O7 
C 2 1079 712 
C 1128 724 1.56 
ML~ 1097 719 1.53 
C 1 1701 8146 
C 2 1747 8392 
C 1693 8300 0 .20 
ML~ 1803 8476 0.21 
C 1 1943 2008 
C 2 1898 1997 
C 1922 1981 0.97 
ML~ 1940 1981 0.98 
C 1 278 462 
C 2 271 468 
C 278 459 0.61 
ML~ 299 479 0.62 
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Incubation 2 
Following initial chromatography in system 3, the material in 
hold back volume (HBV) I from the experimental and control flasks 
was found t0 contain only a 3H-label. The amount of radioactivity 
recovered expressed as a percent of the 3H-labeled radioactivity in- 
cubated, represents the degree of solvolysis occurring under these 
conditions. The amount of solvolysis in the control flasks was 0.31% 
and 0.32%.(tissueless and inactivated tissue control flasks respect- 
ively) aud in the experimental flask 0.59%. The amount of sulfatase 
activity present in fetal testes under these incubation conditions 
is slight (approximately 0.27%). 
In addition to this small amount of radioactivity in HBV I of 
each control incubation, an area of activity corresponding to the 
starting material (PS) was identified. No other areas of radioac- 
tivity were noted in the control incubations. The material in HBV I 
from the experimental flask was submitted to PC in a variety of systems. 
Pregnenolone and androstenedione were tentatively identified. 
From the experimental flask, areas of radioactivity were noted 
in HBV IV to VI and HBV X to XII. The largest (HBV IV to VI) corres- 
ponded in mobility to carrier PS. The mobility of the radioactive 
material in the other area (HBV X to XIII), corresponded to carrier 
17~-OH-PS and DHAS. After conversion to the pyridinium salt, the 
PS-like material was submitted to CPC in system i0. The area (HBV II 
to III) corresponding to carrier PS was submitted to PC in system 4 
and behaved in an identical manner to PS. This material was recrystal- 
lized to constant SA after further addition of crystalline PS (Table 4). 
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Table 4. Radiochemical purity of 17~-hydroxypregnenolone sulfate 










Solvent lization cpm 3H/mg cpm 35S/mg* 3H/355 
Methanol C 1 13683 1875 
Ethanol C 2 13021 1994 
Methanol C 3 12820 1919 6.68 
ML 3 13638 2000 6.82 
Methanol C 1 999 157 
Methanol, 





C 3 994 147 6.76 
ML 3 972 147 6.61 
* cpm of 35S are corrected for decay 
** starting material 
The area corresponding to 17a-OH-PS and DNAS was submitted to 
CPC in system i0. Four zones of radioactivity were isolated. Zone I 
(HBV VIII to X) was resubmitted to CPC in system 3. Two areas of 
radioactivity were found. The less polar (HBV IX and X) was identical 
to carrier 17a-ON-PS and, after further addition of cold carrier, was 
recrystallized to constant SA (Table 4). 
Zone 2 (HBV IV to VI) was solvolyzed and submitted to PC in system 
4. An area similar to DHAS carrier was rechromatographed in system 4 
after authentic DHAS carrier had been added. This material was solvol- 
yzed and submitted to PC in system 9. A small peak of radioactivity 
with a mobility identical to carrier DHA was noted, but the small amount 
of radioactivity precluded definitive identification. 
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The remaining two zones of polar radioactive material (HBV I and 
HBV II to III) were investigated further buc the identity of this 
material could not be established. 
DISCUSSION 
The demonstration in the first incubation that approximately 
6% of the recovered tritium was in the organic fraction suggests the 
presence of sulfatase activity. The 3H/14C ratios of the unconJugated 
C-21 and C-19 steroids identified (Table 3) are noted to vary, but 
both labels are present in the final recrystallization of each metabolite 
indicating that both conjugated and unconjugated pregnenolone served 
as precursors in the formation of these unconjugated metabolites. 
The inconsistency in the 3H/14C ratios derived from the recrystallization 
data for 17a-hydroxypregnenolone and 17~-hydroxyprogesterone cannot 
be explained readily. Sulfatase activity was demonstrated in the 
second incubation as well, albeit to a lesser degree. 
Sulfatase activity has been found in placenta (29,30), human fetal 
adrenals near term (29), and adult testes (23,31). That fetal perfusion 
studies have failed to demonstrate sulfatase activity may be explained 
either by the inability of the steroid sulfate to gain entrance to 
the site of enzyme action or by the fact that whole body perfusions 
were performed and the activity of any one organ, particularly one 
which may contribute quantitatively small amounts to the total steroid 
pool, may be difficult to assess. 
14C could not be demonstrated in either of the two steroid sulfate 
metabolites identified (DHAS and pregnenediol sulfate). In in vivo 
perfusion studies with labeled pregnenolone Solomon et al (32) isolated 
several sulfurylated steroids from a variety of fetal tissues; however, 
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the fetal gonad was not specifically studied. In a fetal perfusion 
with labeled 17~-hydroxypregnenolone, Pion et al recovered 17~-OH-PS 
and DHAS from adrenals, perfusate and residual tissue (5). Recently, 
the de novo formation of testosterone and cholesterol from acetate 
was demonstrated in the human fetal testis, but no sulfo-conJugated 
steroids were found (33). These findings are in contrast to our earlier 
studies in the human fetal adrenal (34) in which the de novo synthesis 
of both free and sulfurylated steroids was demonstrated. A high degree 
of sulfurylating activity in endocrine and non-endocrlne fetal tissues 
has been reported (1-4). Our findings would suggest that under the 
experimental conditions employed the fetal testis, unlike other fetal 
tissues, possess little sulfokinase activity. 
In the second incubation, the direct conversion of pregnenolone 
3 35 
-3H-sulfate-35S to 17~-hydroxypregnenolone- H-sulfate- S has been 
demonstrated. Conversion of PS, which is present in large amounts 
in the umbilical artery (1), to 17~-OH-PS, DHAS, and 16~-hydroxydehydro- 
epiandrosterone sulfate has been demonstrated in a similar fetal adrenal 
incubation in this laboratory (22). The importance of steroid sulfates 
in other tissues as precursors of other steroid sulfates (12-16,21,35) 
as well as biologically active hormones (17-20) has been noted. Steroid 
sulfates may play similar important roles in the fetal testis. 
The work of Jost (36) has offered convincing evidence that androgens 
are necessary for the development and differentiation of the internal 
and external genitalia in the male fetus. Since in the fetal circulation 
steroids are present largely as sulfates, sulfatase activity in the 
fetal testis as demonstrated in this study may play a significant 
role in the biogenesis of free, biologically active androgens for this 
p u r p o s e .  
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(5) The following abbreviations and trivial names are used: 
preguenolone (38-hydroxypregn-5-en-20-one), pregnenolone sulfate (PS) 
(20-oxo-pregn-5-en-38-yl-sulfate), 17a-hydroxypregnenolone (38,17a- 
dihydroxypregn-5-en-20-oue), 17a-hydroxypregnenolone acetate (17a- 
hydroxy-20-oxo-pregn-5-en-38-yl-acetate), 17a-hydroxypregnenolone sul- 
fate (17a-OH-PS) (17a-hydroxy-20-oxo-pregn-5-en-38-yl-sulfate), preg- 
nenediol diacetate (5-pregnene-38,20a-diol diacetate), pregnenediol 
sulfate (20a-hydroxy-pregn-5-en-38-yl-sulfate), dehydroepiandrosterone 
(DHA) (38-hydroxyandrost-5-en-17-one), dehydroepiandrosterone sulfate 
(DHAS) (17-oxo-androst-5-en-38-yl-sulfate), 16a-hydroxydehydroepi- 
androsterone sulfate (16a-hydroxy-17-oxo-androst-5-en-38-yl-sulfate), 
progesterone (pregn-4-en-3,20-dione), 17a-hydroxyprogesterone (17a- 
hydroxypregn-4-en-3,20-dione), androstenedione (androst-4-en-3,17- 
dione), testosterone (!78-hydroxyandrost-4-en-3-one). 
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